MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TNON Stock advanced +1.33% Today — RQD Quant Desk Flash
$2.29 +1.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.29
Tenon Medical Inc. (TNON) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $6.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.29 (+0.05%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNON)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY TNON SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.5 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$3.41-20.8% Next Q
51
Q2 (-2Q)Grade D$2.70-18.5% Next Q
48
Q3 (-1Q)Grade D$2.20+4.1% Next Q
46
CurrentGrade D-$2.29-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TNON Turnaround Squeeze
While TNON currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.67) and Max Pain ($2.40) forces dealer call-delta covering toward $47.77.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TNON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TNON Stock advanced +1.33% Today — RQD Quant Desk Flash
Tenon Medical Inc. (TNON) advanced +1.33% to $2.29, trading at 2% of its 52-week range ($2.05 – $45.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.05 – $45.5) with RSI-14 at 33.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 59.8% gross margin and $0 annual free cash flow.
Live TNON Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNON)
- ✓Walkthrough of TNON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TNON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.44%🛡️ HOLDING TREND SUPPORT
2026-10-30O $2.27H $2.29L $2.05C $2.29VOL 169.0K
RES: $5.20SUP: $1.58SMA50: $3.67SMA200: $17.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TNON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TNON today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TNON. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNON)
Health Care Rank #562 of 1016
⚔️ INBS vs TNON Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TNON vs. INBS, SNOA, WOK, NVNO)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tenon Medical Inc. (TNON) ranks #562 by composite RQD confidence (43/100, grade D-) and #926 by equity capitalization ($6.2M). Within this direct 5-issuer industry benchmark cohort, TNON leads on earnings valuation at N/A trailing P/E, while TNON leads on capital efficiency and profitability with -35.0% ROIC and 59.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with TNON at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TNON
ACTIVE
Tenon Medical Inc. | D- | 43/100 | — | 59.8% | -35.0% | +1.33% | $6.2M | Benchmark Subject |
| INBS Intelligent Bio Solutions Inc. | D- | 38/100 | — | 40.8% | -35.0% | +9.58% | $6.1M | /inbs-vs-tnon → |
| SNOA Sonoma Pharmaceuticals Inc. | D | 44/100 | — | 38.0% | -35.0% | +5.26% | $5.7M | /snoa-vs-tnon → |
| WOK WORK Medical Technology Group LTD (Class A) | D+ | 54/100 | — | — | — | -4.35% | $4.9M | /wok-vs-tnon → |
| NVNO enVVeno Medical Corporation | D | 50/100 | — | — | -35.0% | +4.08% | $4.9M | /nvno-vs-tnon → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560293In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenon Medical Inc. (TNON) reported GAAP revenue of $3.9M (+20.4% vs. FY2024 revenue of $3.3M , and +34.7% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$10.7M, and free cash flow of -$11.0M (-9.5% YoY). On the balance sheet, TNON closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.9M | -$12.6M | -$10.7M | -$11.0M | $10.8M | — |
| FY2024 (FY) | 2024-12-31 | $3.3M | -$13.7M | -$9.9M | -$10.1M | $9.8M | — |
| FY2023 (FY) | 2023-12-31 | $2.9M | -$15.6M | -$12.2M | -$12.2M | — | — |
3. TNON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Tenon Medical Inc. (NASDAQ: TNON) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.29 (+1.33% 1D, market cap $6.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNON ranks #562 in composite RQD confidence.
How does TNON compare to INBS and SNOA in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, INBS (Intelligent Bio Solutions Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TNON?
Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TNON trading relative to its 50-day, 200-day, and 52-week technical levels?
TNON last traded at $2.29 (+1.33% on volume of 126,226 shares), positioning the stock -37.60% below its 50-day simple moving average ($3.67) and -86.60% below its 200-day simple moving average ($17.09). Across its 52-week range of $2.05 to $45.50, TNON sits at the 0.6% percentile with a 14-day RSI of 33.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.00 to $2.58).
TNON Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TNON stock moving today?
Why TNON Stock advanced +1.33% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.